Potent antihyperglycaemic activity of calocybe indica in streptozotocin induced diabetic rats antihyperglycemic activity of calocybe indica

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 5, Issue 2, 2013, Pages 512-515

  Rajeswari, Paramasivam ^a   Krishnakumari, Shanmugasundaram ^a  

^a KONGUNADU ARTS AND SCIENCE COLLEGE   (India)

Author keywords

Antidiabetic activity; Calocybe indica; Mushroom; Streptozotocin nicotinamide induced diabetes mellitus

Indexed keywords

CALOCYBE INDICA EXTRACT; FUNGAL EXTRACT; GLIBENCLAMIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; INSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CALOCYBE INDICA; CONTROLLED STUDY; DIABETES MELLITUS; EOSINOPHIL COUNT; FEMALE; HEMATOCRIT; LIFESPAN; LYMPHOCYTE COUNT; MEDICINAL MUSHROOM; MONOCYTE; MORTALITY; NEUTROPHIL COUNT; NONHUMAN; RAT; SURVIVAL RATE; THROMBOCYTE COUNT;

EID: 84875963575     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E et al. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gyn. Oncol 2006; 101: 55-61.
2. Ferreira ICFR, Baptista P, Vilas-Boas M, Barros L Free-radical scavenging capacity and reducing power of wild edible mushrooms from northeast Portugal. Food Chem 2007; 100: 1511-1516.
3. Sadler M Nutritional properties of edible fungi. Nutr. Bull 2003; 28: 305-308.
4. Borchers AT, Keen CL, Gershwin ME Mushrooms, Tumors, and Immunity: An Update. Exp. Biol. Med 2004; 229: 393-406.
5. Lteif A, Mather K Insulin resistance, metabolic syndrome and vascular diseases: Update on mechanistic linkages. Can. J. Cardiol 2004; 20: 66B-76B.
6. Tsukamoto S, Macabalang AG, Nakatani K, Obara Y, Nakahata N, Ohta T Tricholomalides A-C, new neurotrophic diterpenes from the mushroom Tricholoma sp. J. Nat. Prod 2003; 66: 1578-1581.
7. Purkayastha RP, Chandra A A new species of edible mushroom from India. Trans. Br. Mycol. Soc 1974; 62: 415-418.
8. Vamsikrishna AN, Ramgopal M, Raman BV, Balaji M Antidiabetic efficacy of ethanolic extract of Phragmites vallatoria on STZ induced diabetic rats. Int J Pharm Pharm Sci 2012; 4 suppl. 1: 118-120.
9. Shaw JE, Sicree RA, Zimmet PZ Global estimates of the prevalence of diabetes for 2010 and 2030. Diab. Res. Clin. Prac 2010; 87: 4-14.
10. Panunti B, Jawa AA, Fonseca VA Mechanisms and therapeutic targets in type 2 diabetes mellitus. Drug Discov. Today Dis Mech 2004; 1: 151-157.
11. Obaid M, Turtle JR Type 2 diabetes: an epidemic in the making. ADF 2004; 5: 29-34.
12. Ogbonnia SO, Odimegwu JI, Enwuru VN Evaluation of hypoglycemic and hypolipidemic effects of ethanolic extracts of Treculia africana Decne and Bryophyllum pinnatum Lam. and their mixture on streptozotocin (STZ)-induced diabetic rats. Afr. J. Biotechnol 2008; 7 suppl 15: 2535-2539.
13. Edem DO Hypoglycemic Effects of Ethanolic Extracts of Alligator Pear Seed (Persea Americana Mill) in Rats. Eur. J. Sci. Res 2009; 33 suppl 4: 669-678.
14. Alberti KG, Zimmet PZ Definition, diagnosis and classification of Diabetes Mellitus and its complications. Diab. Care 1998; 15: 539-53.
15. Grover JK, Yadav S, Vats V Medicinal plants of India with anti-diabetic potential. J. Ethnopharmacol 2002; 81: 81-100.
16. Sarasa D, Sridhar S, Prabakaran E Effect of an antidiabetic extract of Trigonella foenum-graecum on normal and alloxan induced diabetic mice. Int J Pharm Pharm Sci 2012; 4 suppl. 1: 63-65.
17. Vestergaard P Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteopor. Internl 2007; 18: 427-44.
18. Kawahara R Glycohemoglobin (HbA1c, HbA1). Nippon Rinsho 1998; 56 suppl 3: 55-58.
19. Aso Y, Inukai T, Tayama K, Takemura Y Serum concentrations of advanced glycosylation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000; 37: 87-92.
20. McCarter R, Hempe J, Gomez R, Chalew SA Hemoglobin Glycosylation Index is a predictor of complications in the DCCT (Abstract). Diabetes 2000; 49 suppl 1: A48.
21. Almoznino-Sarafian D, Shteinshnaider M, Tzur I, Bar-Chaim A, Iskhakov E, Berman S et al. Anemia in diabetic patients at an internalmedicineward: clinical correlates and prognostic significance. Eur. J. Intern. Med 2010; 21 suppl 2: 91-6.
22. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proceedings of the National Academy of Sciences of the United States of America 1994; 91: 7742-6.
23. Ohshita K, Yamane K, Hanafusa M, Mori H, Mito K, Okubo, M et al. Elevated white blood cell count in subjects with impaired glucose tolerance. Diab. Care 2004; 27: 491-496.
24. Pertynska-Marczewska M, Kiriakidis S, Wait R, Beech J, Feldmann M, Paleolog EM Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages. Cytokine 2004; 28: 35-47.
25. Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI Association of diabetes and hepatitis C infection: Epidemiologic evidence and pathophysiologic insights. Curr. Diab. Rep 2004; 4 suppl 3: 194-198.
26. Geerlings SE, Hoepelman AI Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol. and Med. Microbiol 1999; 26 suppl 3-4: 259-265.
27. Andersen B, Goldsmith GH, Spagnuolo PJ Neutrophil adhesive dysfunction in diabetes mellitus; the role of cellular and plasma factors. J. Lab. Clin. Med 1988; 111 suppl 3: 275-285.
28. Casey JI, Heeter BJ, Klyshevich KA Impaired response of lymphocytes of diabetic subjects to antigen of Staphylococcus aureus. J. Inf. Dis 1977; 136 suppl 4: 495-501.
29. Anthony JG, Hanley, Ravi Retnakaran, Ying Qi, Hertzel C, Gerstein et al. Association of Hematological Parameters with Insulin Resistance and β-Cell Dysfunction in Nondiabetic Subjects. J. Clin. Endocrinol. Metabol 2009; 94: 3824-32.
30. Danesh J, Collins R, Peto R, Lowe GDO Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 2000; 21: 515-20.
31. Salazar-Vazquez BY, Intaglietta M, Rodriguez-Moran M, Guerrero-Romero F Blood pressure and hematocrit in diabetes and the role of endothelial responses in the variability of blood viscosity. Diab. Care 2006; 29: 1523-8.